<DOC>
	<DOCNO>NCT02174354</DOCNO>
	<brief_summary>Methotrexate ( MTX ) widely prescribe treat inflammatory condition include psoriasis , recommend first-line systemic therapy moderate-to-severe disease . Approximately 40 % patient psoriasis sub-optimal response MTX significant number experience side effect may include derange liver enzymes . There currently validate test predict patient psoriasis respond MTX , term disease outcome and/or toxicity , guide dose escalation group .</brief_summary>
	<brief_title>Methotrexate Polyglutamates Marker Clinical Response Toxicity Treatment Psoriasis</brief_title>
	<detailed_description>Data study drawn BSTOP ( Biomarkers Systemic Treatment Outcomes Psoriasis ) cohort . This multi-centre , prospective , cohort study establish clinically relevant biomarkers pharmacogenetic marker systemic treatment outcomes patient severe psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients psoriasis Taking oral subcutaneous methotrexate Measurement methotrexate polyglutamates least one occasion therapy . Patients give write informed consent Unable consent Not take methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Methotrexate Polyglutamates</keyword>
	<keyword>Injury Liver</keyword>
</DOC>